Flatiron Health, Inc.

Flatiron Health, a Roche subsidiary since 2018, develops OncoEMR, a specialized electronic health record system designed exclusively for oncology practices and cancer treatment centers. The platform serves as both a clinical documentation tool and a real-world evidence generation engine, distinguishing it from general-purpose EMR systems through deep integration with cancer-specific workflows and data collection requirements.

OncoEMR is built specifically for oncology workflows, offering structured data capture for chemotherapy ordering, radiation therapy planning, tumor board documentation, clinical trials management, and survivorship care plans. The system maintains comprehensive cancer registry integration and supports complex oncology-specific protocols including NCCN guidelines and clinical pathways. Unlike traditional EMRs that add oncology modules as afterthoughts, OncoEMR's architecture centers entirely on cancer care delivery.

The platform's primary differentiator lies in its dual-purpose design: while functioning as a clinical EMR, it simultaneously aggregates de-identified patient data into Flatiron's real-world evidence network, which contains curated data from over 280 cancer clinics and 3 million active cancer patients in the United States. This positions Flatiron uniquely at the intersection of clinical operations and research, enabling participating practices to contribute to and access insights from one of the largest oncology data networks globally.

Flatiron primarily targets community oncology practices, academic cancer centers, and hospital-based oncology departments ranging from single-site practices to large multi-location networks. The system is cloud-based (SaaS deployment), eliminating the need for on-premises infrastructure and enabling rapid implementation compared to legacy enterprise EMRs. Integration capabilities include HL7 FHIR standards, direct connections to Foundation Medicine for genomic testing integration (leveraging Roche's portfolio), and APIs for connecting to existing practice management and billing systems.

The acquisition by Roche strengthened Flatiron's position in precision medicine and biomarker-driven oncology, particularly through connections to diagnostic platforms and pharmaceutical development pipelines. This relationship provides unique value for practices participating in clinical trials or seeking access to modern treatment protocols. The platform is particularly strong in medical oncology and hematology workflows, though it also supports radiation oncology and surgical oncology documentation.

Market position reflects a focused strategy: rather than competing broadly across all specialties, Flatiron dominates the oncology-specific EMR niche, with hundreds of community practices and several major cancer center partnerships. The system's research data contribution model means practices gain access to benchmarking, quality metrics, and real-world evidence insights that would be difficult to obtain independently, creating a network effect that strengthens as more practices adopt the platform.